Search results
New drug therapy ‘highly effective’ for young children with severe eczema
Press Association News via AOL· 2 years agoA new drug therapy to treat moderate to severe eczema in young children has been shown to be “safe...
Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease
Zacks via Yahoo Finance· 1 year agoSanofi SNY and partner Regeneron REGN announced that the Committee for Medicinal Products for Human...
Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review
Zacks via Yahoo Finance· 1 year agoSanofi SNY announced that the supplemental biologics license application (sBLA) for the label...
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients
Benzinga via Yahoo Finance· 2 years agoASLAN Pharmaceuticals (NASDAQ: ASLN) plans to initiate a new clinical trial of eblasakimab for...
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
Benzinga via Yahoo Finance· 1 year agoThe UK's Medicines and Healthcare Regulatory Agency (MHRA) warned of some new and severe eye-related...
The Most Exciting New Advances in Managing COPD
Time via Yahoo News· 1 month agoCredit - Karl Tapales—Getty Images The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, is the world’s preeminent COPD research and...
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
Benzinga via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Phase 3 trial of Dupixent...
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Benzinga via Yahoo Finance· 1 year agoThe European Commission approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's...
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
Benzinga via Yahoo Finance· 2 years agoThe FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent...
Pharma Stock Roundup: LLY's Alzheimer's Study Setback, FDA Updates for SNY, MRK
Zacks via Yahoo Finance· 1 year agoThis week, Eli Lilly’s LLY candidate, solanezumab, failed to prevent Alzheimer’s in a study. Merck’s...
